Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer
Open Access
Abstract
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading cause of male cancer-related mortality. Unlike many cancers, prostate cancer lacks clear genetic driver mutations, suggesting that factors in the tumor microenvironment contribute to the genesis and progression of this disease. Hypoxia, or a physiological state of low oxygen, is a universal characteristic of solid tumors that enhances disease progression and therapeutic resistance. Prostate cancer develops in a hypoxic microenvironment and primarily metastasizes to bone, where oxygen availability is similarly limited. Therefore, hypoxia is a major obstacle to the effective treatment of prostate cancer across all disease stages. Clinically, hypoxia is correlated with worse patient outcomes, largely because it drives resistance to the frontline therapies used to treat both primary and metastatic prostate cancer. Despite the established role of hypoxia in prostate cancer progression and drug resistance, it has not been successfully targeted therapeutically. Emerging evidence indicates that exposure to distinct temporal patterns of hypoxia (acute, cyclic, and chronic) elicits unique cellular adaptations that dictate tumor growth and survival. This review synthesizes current evidence regarding the role of hypoxia in promoting resistance to therapy in prostate cancer.Keywords
Funding Information
- U.S. Department of War (HT9425-25-1-0098)
This publication has 196 references indexed in Scilit:
- Cancer cells employ lipid droplets to survive toxic stressThe Prostate, 2024
- Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical ProstatectomyJAMA Network Open, 2023
- Hot and cold tumors: Immunological features and the therapeutic strategiesMedcomm, 2023
- Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2The Journal of Pathology, 2020
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- The CAPRA‐S scoreCancer, 2011
- The laminin binding integrin α6β1 in prostate cancer perineural invasionJournal of Cellular Physiology, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Combined androgen blockade with bicalutamide for advanced prostate cancerCancer, 2009
- Adjuvant Radiotherapy for Pathologically Advanced Prostate CancerJAMA, 2006